Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Buy” from Analysts
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has been assigned an average recommendation of “Buy” from the six analysts that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in the […]
More Stories
Trump Says US-UK Trade Deal ‘Signed and Done’ at G7 Summit
By Emel Akan CALGARY, Canada—President Donald Trump announced on Monday that the recently finalized UK-US bilateral trade agreement is “signed...
Former New York Assembly Candidate Charged With Campaign Finance Fraud
By Frank Fang A Chinese national allegedly stole around $162,000 in taxpayer money to fund his 2024 campaign for New...
7 Best Delivery Apps to Make Money in 2025
In the current fast-paced world, side hustles have become an increasingly popular means of earning extra cash, specifically, food delivery...
NorthCrest Asset Manangement LLC Buys 4,007 Shares of Altria Group, Inc. (NYSE:MO)
NorthCrest Asset Manangement LLC increased its stake in shares of Altria Group, Inc. (NYSE:MO – Free Report) by 88.5% in...
CVA Family Office LLC Reduces Stake in Phillips 66 (NYSE:PSX)
CVA Family Office LLC decreased its stake in shares of Phillips 66 (NYSE:PSX – Free Report) by 11.4% during the...
NorthCrest Asset Manangement LLC Lowers Stock Holdings in U.S. Bancorp (NYSE:USB)
NorthCrest Asset Manangement LLC trimmed its stake in U.S. Bancorp (NYSE:USB – Free Report) by 7.0% in the 1st quarter,...